Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Restoration of Non-carious Cervical Lesions With Different Resin Composites and Universal Adhesive

NCT06393699 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2022-05-14
Last updated
2025-02-27

Condition(s) studied

Retention

Investigational drug(s) / intervention(s)

composite restoration

composite restoration: different types of resin composite restorations will be used to restore NCCL

Study summary

patients with non carious cervical lesions suffer from dentin sensitivity and presence of cavitations and gingival recession. Restoring these lesions with different composites and evaluation of restorations every 6 months will be done to know the effect of different composite types and consistencies in retention of restorations of such lesions.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: \- Patients' age will range from 18 to 65 years. * Presence of at least 2 NCCLs in one side. * Patients with no medical condition could interfere with the routine dental care. * Patients who will be able to attend for each recall visit. * Patients with healthy periodontal tissues. * Cavities presenting no more than 50% of margins in enamel. Exclusion Criteria: * Medically compromised patients. * Pregnant or breast-feeding patients. * Patients undergoing orthodontic treatment or bleaching treatment in the time of the study. * Patients with periodontal disease in the target area. * Patients presented with less than 20 teeth in the oral cavity. * Patients without antagonists. * Lesions superimposed with caries

Primary outcome measure(s)

  • Retention — 18-24 months
    ability of resin composite restorations to be retained in the non carious cervical lesions

Trial sites (1)

FacilityCityRegionStatus
Ain shams university Cairo Egypt Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06393699 on ClinicalTrials.gov ↗ ← All trials in Egypt